141 related articles for article (PubMed ID: 38376572)
21. Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia.
Zacholski K; Hambley B; Hickey E; Kashanian S; Li A; Baer MR; Duong VH; Newman MJ; DeZern A; Gojo I; Smith BD; Levis MJ; Varadhan R; Gehrie E; Emadi A; Ghiaur G
J Oncol Pharm Pract; 2022 Sep; 28(6):1340-1349. PubMed ID: 34134554
[TBL] [Abstract][Full Text] [Related]
22. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
[TBL] [Abstract][Full Text] [Related]
23. Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment.
Wang HX; Duan LN; Ji SQ; Guo ZK
Leuk Lymphoma; 2006 Jul; 47(7):1438-40. PubMed ID: 16923589
[No Abstract] [Full Text] [Related]
24. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
25. Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment.
Zhang Z; Zhang S; Zhang F; Zhang Q; Wei H; Xiu R; Zhao Y; Sui M
Biol Trace Elem Res; 2024 Jan; 202(1):122-132. PubMed ID: 37097388
[TBL] [Abstract][Full Text] [Related]
26. [Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia].
Korístek Z; Zák P
Vnitr Lek; 2008; 54(7-8):745-50. PubMed ID: 18780573
[TBL] [Abstract][Full Text] [Related]
27. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
Zhang Y; Wu S; Luo D; Zhou J; Li D
PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
[TBL] [Abstract][Full Text] [Related]
28. Overcoming treatment resistance in acute promyelocytic leukemia and beyond.
Fung TK; So CW
Oncotarget; 2013 Aug; 4(8):1128-9. PubMed ID: 23934744
[No Abstract] [Full Text] [Related]
29. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.
Eghtedar A; Rodriguez I; Kantarjian H; O'Brien S; Daver N; Garcia-Manero G; Ferrajoli A; Kadia T; Pierce S; Cortes J; Ravandi F
Leuk Lymphoma; 2015 May; 56(5):1342-5. PubMed ID: 25120050
[TBL] [Abstract][Full Text] [Related]
30. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
Patel SP; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovek S; Kantarjian H; Estey E
Leuk Res; 2006 Mar; 30(3):362-3. PubMed ID: 16168477
[No Abstract] [Full Text] [Related]
31. Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.
Chendamarai E; Ganesan S; Alex AA; Kamath V; Nair SC; Nellickal AJ; Janet NB; Srivastava V; Lakshmi KM; Viswabandya A; Abraham A; Aiyaz M; Mullapudi N; Mugasimangalam R; Padua RA; Chomienne C; Chandy M; Srivastava A; George B; Balasubramanian P; Mathews V
PLoS One; 2015; 10(3):e0121912. PubMed ID: 25822503
[TBL] [Abstract][Full Text] [Related]
32. Derivative 6 as an additional chromosomal abnormality along with t(15;17): A case report.
Dalvi RC; Mandava S; Pais AP; Kokate PP; Sinha N; Nath UK
Indian J Cancer; 2022; 59(3):419-421. PubMed ID: 36412315
[TBL] [Abstract][Full Text] [Related]
33. [Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
Haanen C; Vermes I
Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1738-41. PubMed ID: 10494320
[TBL] [Abstract][Full Text] [Related]
34. Arsenic: a new place?
Vincent PC
Pathology; 1999 May; 31(2):81-2. PubMed ID: 10399159
[No Abstract] [Full Text] [Related]
35. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD
Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204
[TBL] [Abstract][Full Text] [Related]
36. Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia.
Li SY; Lu Y; Liu HC; Gang EJ; Le J; Qian SY; Tang SH; Si T; Pei RZ
Leuk Lymphoma; 2021 May; 62(5):1267-1270. PubMed ID: 33439058
[No Abstract] [Full Text] [Related]
37. Sulfhydryl compound levels are associated with ATO-induced side effects in acute promyelocytic leukemia patients.
Sui M; Wei H; Shen X; Gao K; Zhang Z; Zhang Q
Hematology; 2023 Dec; 28(1):2231738. PubMed ID: 37417768
[TBL] [Abstract][Full Text] [Related]
38. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021.
Gill H; Raghupathy R; Lee CYY; Yung Y; Chu HT; Ni MY; Xiao X; Flores FP; Yim R; Lee P; Chin L; Li VWK; Au L; Au WY; Ma ESK; Mohan D; Kumana CR; Kwong YL
BMC Cancer; 2023 Feb; 23(1):141. PubMed ID: 36765318
[TBL] [Abstract][Full Text] [Related]
39. Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.
Li J; Zhu H; Hu J; Mi J; Chen S; Chen Z; Wang Z
Int J Hematol; 2014 Jul; 100(1):38-50. PubMed ID: 24938378
[TBL] [Abstract][Full Text] [Related]
40. [Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia].
Wang HY; Zhang HY; Liu Y; Zhang XX; Gong S; Chen LM; Wang MC; Xi JY; Liu X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):705-709. PubMed ID: 29950207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
